tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating Backed by Strong Q4 Execution, Early Aqvesme Momentum, and Multi-Asset Clinical Catalyst Upside
PremiumRatingsBuy Rating Backed by Strong Q4 Execution, Early Aqvesme Momentum, and Multi-Asset Clinical Catalyst Upside
27d ago
Agios Pharmaceuticals files automatic mixed securities shelf
Premium
The Fly
Agios Pharmaceuticals files automatic mixed securities shelf
27d ago
Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating
Premium
Ratings
Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating
28d ago
Vorasidenib’s Real-World Test in Germany: What Agios Investors Should Watch
PremiumCompany AnnouncementsVorasidenib’s Real-World Test in Germany: What Agios Investors Should Watch
2M ago
Agios Pharma Sets 2026 Strategic Priorities After AQVESME Approval
Premium
Company Announcements
Agios Pharma Sets 2026 Strategic Priorities After AQVESME Approval
2M ago
Agios Pharmaceuticals outlines 2026 strategic priorities
Premium
The Fly
Agios Pharmaceuticals outlines 2026 strategic priorities
2M ago
Agios: FDA Approval of Aqvesme in Thalassemia Unlocks Transformational Market Opportunity, Supporting Buy Rating and Higher Target
PremiumRatingsAgios: FDA Approval of Aqvesme in Thalassemia Unlocks Transformational Market Opportunity, Supporting Buy Rating and Higher Target
3M ago
Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright
Premium
The Fly
Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright
3M ago
Agios Pharmaceuticals price target raised to $38 from $32 at Truist
Premium
The Fly
Agios Pharmaceuticals price target raised to $38 from $32 at Truist
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100